Filter results by

Guidance and Policy (3126)
Guidance (942)
Policy and Strategy (2058)
Quality Indicators (107)
Prescribing and Technical Information (153)
Secondary Evidence (829)
Evidence Summaries (780)
Evidence Uncertainties (53)
Primary Research (346)
Practice Based Information (145)
Case Studies (145)
Medicines Current Awareness (74)
Implementation Support (2046)
Information for the Public (1419)
Patient Decision Aids (9)

Area of interest

Clinical (1298)
Public Health (128)

Drugs and Technologies (53)

Source

Department of Health (0)
Centre for Mental Health (0)
Renal Association (0)
NIHR Dissemination Centre (0)
Monitor (0)
National Institute for Health and Care Excellence - NICE (53)

Date

From

To

View filters

Results for all evidence | National Institute for Health and Care Excellence - NICE | Drugs and Technologies | Evidence Uncertainties 1 - 10 of 53 sorted by relevance / date

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Warning, download options selected.

The operation that you have selected will move away from the current results page, your download options will not persist.

Please click "Confirm" if you are happy to lose these search results.

Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319/2)

Remove: National Institute for Health and Care Excellence - NICE source - 01 July 2014

Recommendation ID TA319/2 Question Further research into whether concomitant dacarbazine enhances the clinical effectiveness of ipilimumab

Remove: Evidence Uncertainties filter
Ticagrelor for the treatment of acute coronary syndromes (TA236/2)

Remove: National Institute for Health and Care Excellence - NICE source - 01 October 2011

Recommendation ID TA236/2 Question Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups

Remove: Evidence Uncertainties filter
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 January 2019

Recommendation ID TA556/1 Question Further research is recommended to resolve the uncertainties about the long-term clinical effectiveness

Remove: Evidence Uncertainties filter
Degarelix for treating advanced hormone-dependent prostate cancer (TA404/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 August 2016

Recommendation ID TA404/1 Question Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix

Remove: Evidence Uncertainties filter
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 November 2013

Recommendation ID TA301/1 Question Further research is recommended to resolve uncertainties about the cost effectiveness of fluocinolone

Remove: Evidence Uncertainties filter
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 February 2011

Recommendation ID TA214/1 Question Further research designed to investigate differences in health-related quality of life and the clinical

Remove: Evidence Uncertainties filter
Mifamurtide for the treatment of osteosarcoma (TA235/2)

Remove: National Institute for Health and Care Excellence - NICE source - 01 October 2011

Recommendation ID TA235/2 Question Further collection of quality of life data from people who are cured and who have experience of amputation

Remove: Evidence Uncertainties filter
Holoclar for treating limbal stem cell deficiency after eye burns (TA467/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 August 2017

Recommendation ID TA467/1 Question NICE agreed that further research was needed because there is currently no clinical- or cost-effectiveness

Remove: Evidence Uncertainties filter
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 January 2016

Recommendation ID TA375/1 Question NICE agreed that further research would be of value to investigate factors which can predict the likelihood

Remove: Evidence Uncertainties filter
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283/1)

Remove: National Institute for Health and Care Excellence - NICE source - 01 May 2013

Recommendation ID TA283/1 Question NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab

Remove: Evidence Uncertainties filter

1
2
3
4
5
6
Next